重组人血小板生成素与人血丙种球蛋白治疗难治性血小板减少性紫癜

Recombinant human thrombopoietin and human blood gamma globulin in the treatment of refractory thrombocytopenic purpura

目的探讨重组人血小板生成素与人血丙种球蛋白治疗难治性血小板减少性紫癜的临床效果。方法 40例难治性血小板减少性紫癜患者,按照治疗方法的不同分为观察组与对照组,各20例。观察组患者使用人血丙种球蛋白治疗,对照组使用重组人血小板生成素治疗。对比两组患者的治疗效果。结果观察组患者的止血时间、血小板上升时间、血小板恢复时间以及住院时间均短于对照组,差异均具有统计学意义(t=8.4834、4.1321、8.0722、7.0510,P<0.05)。观察组患者的治疗有效率为95%,对照组为85%,对比差异无统计学意义(P>0.05)。结论重组人血小板生成素与人血丙种球蛋白治疗难治性血小板减少性紫癜均可取得良好的效果,但人血丙种球蛋白治疗的见效更快,值得进一步研究推广。

Objective To discuss the clinical effect of recombinant human thrombopoietin and human blood gamma globulin in the treatment of refractory thrombocytopenic purpura.Methods A total of40refractory thrombocytopenic purpura patients were divided by different treatment methods into observation group and control group,with20cases in each group.The research group was treated with human blood gamma globulin,and the control group was treated with recombinant human thrombopoietin.The treatment effect in two groups was compared.Results The observation group had shorter hemostasis time,platelet rise time,platelet recovery time,and hospitalization time than the control group,and their difference had statistical significance(t=8.4834,4.1321,8.0722,7.0510,P<0.05).The observation group had treatment effective rate as95%,which was85%in the control group,and the difference had no statistical significance(P>0.05).Conclusion Both recombinant human thrombopoietin and human blood gamma globulin shows good effect in treating refractory thrombocytopenic purpura,but human blood gamma globulin treatment is more effective.So it is worthy of further research and promotion.